HSCT has been successfully performed as a treatment for EXTL3-CDG and PGM3-CDG immunodeficiency recovering the normal T cell development in these patients and is already approved for PGM3-CDG (59, 60) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback